Amicus Therapeutics and Genpharm Services Sign Distribution Agreement for Galafold for the Treatment of Amenable Patients Living with Fabry Disease

Genpharm Gains Exclusive Rights to Commercialize Migalastat in the Middle East

Dubai, United Arab Emirates – January 2022

Genpharm and Amicus have signed an exclusive partnership under which Genpharm will commercialize Migalastat in the Gulf Cooperation Council. Migalastat has been approved by the European Medicines Agency under the name Galafold^® capsules 123mg for the treatment of patients aged 12 years and older with a confirmed diagnosis of Fabry disease (alpha-galactosidase A deficiency) and who have an amenable mutation. Galafold is the first and only oral precision medicine for Fabry Disease.

“We are thrilled at this partnership with Amicus Therapeutics to bring yet another innovative therapy to our patients. This strengthens our leadership and our portfolio in the rare metabolic disease area with the addition to Migalastat for amenable Fabry disease patients”, says Karim Smaira, Genpharm CEO.

Fabry disease is a rare, progressive genetic disorder characterized by a defective gene (GLA) that causes an enzyme deficiency. This enzyme is responsible for breaking down disease substrate that when deficient in patients with Fabry disease can cause serious complications such as cardiovascular disease, stroke, kidney failure, and even death.

Galafold is approved in over 40 countries around the world, including the U.S., EU, U.K., Japan and others.

About Amicus Therapeutics

Amicus Therapeutics is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering high-quality medicines for people living with rare metabolic diseases. To learn some more go to www.amicusrx.com.